Group 1 - The company signed an exclusive distribution agreement for Lidoderm® with Teikoku Pharma USA, Inc., granting exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm® is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The product is recognized in clinical guidelines for its effectiveness and safety in treating PHN and other neuropathic pain conditions, such as diabetic peripheral neuropathic pain [2][3] Group 2 - PHN is defined as pain persisting for one month or more after the healing of herpes zoster rash, with a significant prevalence among older adults, particularly those aged 60 and above [3] - The company aims to enhance its product portfolio with Lidoderm®, leveraging its brand advantages and existing marketing channels to create synergies and expand into new retail models [5] - The collaboration is expected to positively impact the company's operational performance and align with the interests of its shareholders [5] Group 3 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology, producing over 200 prescription and over-the-counter products [4] - The demand for pain management solutions, particularly for PHN, is significant, and topical patches are well-recognized in the Chinese market for their direct and convenient application [4]

自願性及業務進展公告 簽訂原研藥Lidoderm®利多卡因凝膠貼膏獨家經銷協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本集團」） 欣然宣佈，於二零二六年二月十二日，本集團通過本公司附屬公司與 Teikoku Pharma USA, Inc.（「TPU」, 為日本 Teikoku Seiyaku Co., Ltd（「TSC」，帝國製藥）之附屬公 司，以下合稱「合作方」）就 Lidoderm®利多卡因凝膠貼膏（「產品」）簽訂獨家經銷 協議（「協議」）。 根據協議，本集團獲得該產品在中華人民共和國（就本協議而言，不含香港特別行政區、 澳門特別行政區及臺灣地區，以下簡稱（「目標區域」）內的獨家經銷權利，合作方負 責該產品的生產及供應相關事宜。本協議合作期限首期自該產品在目標區域內首次商業 銷售之日起計十年，到期後根據協議約定續期。 Lidoder ...